Literature DB >> 3722363

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus.

M L Clements, R F Betts, E L Tierney, B R Murphy.   

Abstract

To identify immunological predictors of resistance to influenza A infection and illness, the immunological status of live and inactivated virus vaccines subsequently challenged with H1N1 or H3N2 wild-type virus was examined. We refer to prechallenge antibodies of vaccinees receiving live attenuated virus as infection induced and those receiving inactivated virus as inactivated vaccine induced. Inactivated vaccine-induced protection against wild-type virus infection or illness correlated with the level of neuraminidase-inhibiting antibody in serum, local hemagglutinin immunoglobulin G (IgG) (but not IgA) enzyme-linked immunosorbent assay antibody, and hemagglutination-inhibiting antibody in serum. In contrast, infection-induced resistance to wild-type virus infection correlated with local hemagglutinin IgA antibody and neuraminidase-inhibiting antibody in serum, but not with hemagglutination-inhibiting antibody in serum. These observations suggest that live vaccine virus infection-induced and inactivated vaccine-induced immunity may involve different compartments of the immune system; sufficient antibody in either serum or nasal secretions is capable of conferring resistance.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3722363      PMCID: PMC268857          DOI: 10.1128/jcm.24.1.157-160.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Studies in experimental immunology of influenza. IV. The protective value of active immunization.

Authors:  S FAZEKAS de ST GROTH; M DONNELLEY
Journal:  Aust J Exp Biol Med Sci       Date:  1950-01

2.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

3.  Inactivated influenza vaccines. 2. Laboratory indices of protection.

Authors:  W R Dowdle; M T Coleman; S R Mostow; H S Kaye; S C Schoenbaum
Journal:  Postgrad Med J       Date:  1973-03       Impact factor: 2.401

4.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

5.  Single-dose monovalent A 2 -Hong Kong influenza vaccine. Efficacy 14 months after immunization.

Authors:  H M Foy; M K Cooney; R McMahan; E Bor; J T Grayston
Journal:  JAMA       Date:  1971-08-23       Impact factor: 56.272

6.  Protection with split and whole virus vaccines against influenza.

Authors:  F L Ruben; L W Akers; E D Stanley; G G Jackson
Journal:  Arch Intern Med       Date:  1973-10

7.  Influenza infection in ferrets: role of serum antibody in protection and recovery.

Authors:  P A Small; R H Waldman; J C Bruno; G E Gifford
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

8.  Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.

Authors:  J L Schulman; M Khakpour; E D Kilbourne
Journal:  J Virol       Date:  1968-08       Impact factor: 5.103

9.  Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man.

Authors:  B R Murphy; E G Chalhub; S R Nusinoff; J Kasel; R M Chanock
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

10.  Local and systemic immunity to influenza infections in ferrets.

Authors:  W H Barber; P A Small
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

View more
  141 in total

1.  Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens.

Authors:  Anne M Hutson; Robert L Atmar; Donald M Marcus; Mary K Estes
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.

Authors:  Matthew R Sandbulte; Kim B Westgeest; Jin Gao; Xiyan Xu; Alexander I Klimov; Colin A Russell; David F Burke; Derek J Smith; Ron A M Fouchier; Maryna C Eichelberger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

3.  Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.

Authors:  Jennifer Humberd Smith; Mark Papania; Darin Knaus; Paula Brooks; Debra L Haas; Raydel Mair; James Barry; S Mark Tompkins; Ralph A Tripp
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

4.  Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine.

Authors:  Ana Vujanic; Kenneth J Snibson; Janet L K Wee; Stirling J Edwards; Martin J Pearse; Jean-Pierre Y Scheerlinck; Philip Sutton
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

5.  Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Mitch Phillips; Nicholas V Mendez; Ana Marie Landin; Bonnie B Blomberg
Journal:  Int Immunol       Date:  2012-01-25       Impact factor: 4.823

6.  Influenza update: a review of currently available vaccines.

Authors:  Lisa R Clayville
Journal:  P T       Date:  2011-10

Review 7.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

8.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Role of immunoglobulin A in protection against reovirus entry into Murine Peyer's patches.

Authors:  K J Silvey; A B Hutchings; M Vajdy; M M Petzke; M R Neutra
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 10.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.